Page 12 - 2022 Westchester County Economic Development Guide

One Million Strong Regeneron
Making the World Healthier
As the state’s largest biotech company, Regeneron produces world-class therapeutics to treat diseases like asthma, blindness, cancer and COVID-19.
Above: Regeneron’s Tarrytown campus Opposite, Left: CEO and President,
Dr. Leonard S. Schleifer
Opposite, Top:
Regeneron’s global day of service, Day
for Doing Good Opposite, Bottom: Regeneron advances treatments for chronic and life-threatening diseases.
With more than 10,000 employees, 4,000 of which are located at its Tarrytown-based headquarters, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the state’s largest biotech company. Ranked by Science magazine as the world’s number one employer in the biotech and pharmaceutical industry, the company occupies around 1.8 million square feet of space in Westchester County. It has been recognized as a global corporate responsibility leader through its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the third year in a row.
“Over the past thirty plus years, the Regeneron team has produced numerous FDA-approved medicines, an expansive investigational pipeline and exciting next generation research initiatives like the Regeneron Genetics Center,” says
Regeneron CEO and President, Dr. Leonard S. Schleifer. “Our Tarrytown headquarters is the birthplace of our medicines, including notables like EYLEA for eye diseases, Dupixent for allergic diseases and Libtayo for various cancers – and of course, for REGEN-COV, our investigational COVID-19 therapeutic.”
A YEAR OF MILESTONES
2021 saw a host of significant milestones achieved by the company, including:
Publication by The New England Journal of Medicine of positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COVTM (casirivimab and imdevimab) to treat COVID-19 in infected, high-risk, non-hospitalized patients.
A NIH-sponsored trial found Regeneron’s EYLEA® (aflibercept) injections reduced vision- threatening complications by 68% after two years in diabetic retinopathy patients.
Dupixent received FDA expanded approval as the only biologic medicine to improve lung func- tion in children aged 6-11 with oral corticosteroid- dependent asthma in a randomized Phase 3 trial.
Regeneron and Sanofi announced that the FDA approved the PD-1 inhibitor Libtayo® (cemiplimab- rwlc) for the first-line treatment of patients with advanced non-small cell lung cancer.
With Sanofi, the company received FDA approval for the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as the first immunotherapy treatment indicated for patients with advanced basal cell carcinoma.
The FDA also approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low- density lipoprotein cholesterol (LDL-C) lowering therapies to treat patients aged 12 years and older with hypercholesterolemia.
10
WESTCHESTER COUNTY ECONOMIC DEVELOPMENT GUIDE
© Courtesy of Regeneron